Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELD‐VTE

Inferior vena cava (IVC) thrombosis is a rare form of venous thromboembolism (VTE). The optimal treatment strategies and outcomes are unclear in patients with this presentation.

[1]  R. Mando,et al.  Treatment of May–Thurner’s Syndrome and Associated Complications: A Multicenter Experience , 2021, International journal of general medicine.

[2]  J. P. Carbonell,et al.  Endovascular and medical therapy of May-Thurner syndrome: Case series and scoping literature review. , 2021, Journal de medecine vasculaire.

[3]  S. Desai,et al.  Diagnosis, Clinical Characteristics, and Treatment Modalities of Adolescent May-Thurner Syndrome-associated Deep Venous Thrombosis. , 2020, Journal of pediatric hematology/oncology.

[4]  W. Ageno,et al.  American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. , 2020, Blood advances.

[5]  Alfredo E Farjat,et al.  Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE , 2020, Journal of Thrombosis and Thrombolysis.

[6]  S. Goldhaber,et al.  Endovascular Thrombus Removal for Acute Iliofemoral Deep Vein Thrombosis , 2020 .

[7]  J. Garces,et al.  Abnormal development of the inferior vena cava and its implications on distal venous drainage during cardiac surgery and other clinical entities , 2019, Journal of surgical case reports.

[8]  S. Vedantham.  Catheter-directed thrombolysis to avoid late consequences of acute deep vein thrombosis. , 2017, Thrombosis research.

[9]  S. Goldhaber,et al.  Pharmacomechanical Catheter‐Directed Thrombolysis for Deep‐Vein Thrombosis , 2017, The New England journal of medicine.

[10]  J. Gaynor,et al.  Inferior Vena Cava System Anomalies: Surgical Implications , 2017, Current Urology Reports.

[11]  J. Dowell,et al.  Etiology and treatment of acute inferior vena cava thrombosis. , 2017, Thrombosis research.

[12]  W. Ageno,et al.  Global Anticoagulant Registry in the Field – Venous Thromboembolism (GARFIELD-VTE) , 2016, Thrombosis and Haemostasis.

[13]  M. Alkhouli,et al.  Inferior Vena Cava Thrombosis. , 2016, JACC. Cardiovascular interventions.

[14]  S. Eichinger.  Cancer associated thrombosis: risk factors and outcomes. , 2016, Thrombosis research.

[15]  Elie A Akl,et al.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. , 2012, Chest.

[16]  S. Schulman,et al.  Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH , 2015, Journal of thrombosis and haemostasis : JTH.

[17]  M. Alkhouli,et al.  Comparative Outcomes of Catheter-Directed Thrombolysis Plus Anticoagulation Versus Anticoagulation Alone in the Treatment of Inferior Vena Caval Thrombosis , 2015, Circulation. Cardiovascular interventions.

[18]  John A. Heit,et al.  The epidemiology of venous thromboembolism , 2003, Journal of Thrombosis and Thrombolysis.

[19]  N. Skeik,et al.  Infrahepatic inferior vena cava agenesis with bilateral renal vein thrombosis. , 2013, Annals of vascular surgery.

[20]  B. Lee,et al.  Inferior vena cava thrombosis: A review of current practice , 2013, Vascular medicine.

[21]  Paolo Prandoni,et al.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[22]  K. Bailey,et al.  The association of active cancer with venous thromboembolism location: a population-based study. , 2011, Mayo Clinic proceedings.

[23]  M. Midulla,et al.  Inferior vena cava agenesis and deep vein thrombosis: 10 patients and review of the literature , 2010, Vascular medicine.

[24]  P. Stein,et al.  Incidence of vena cava thrombosis in the United States. , 2008, The American journal of cardiology.

[25]  W. Ageno,et al.  Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry , 2008, Haematologica.

[26]  W. Ageno,et al.  The MASTER registry on venous thromboembolism: description of the study cohort. , 2008, Thrombosis research.

[27]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.

[28]  A. Bura,et al.  Incidence and prognosis of cancer associated with bilateral venous thrombosis: a prospective study of 103 patients , 2004, Journal of thrombosis and haemostasis : JTH.

[29]  M. Armon,et al.  Thrombolysis for acute deep vein thrombosis , 1996, The Cochrane database of systematic reviews.

[30]  A. Lubetsky,et al.  Congenital anomalies of the inferior vena cava revealed on CT in patients with deep vein thrombosis. , 2003, AJR. American journal of roentgenology.

[31]  R. Lipp,et al.  Anomalies of the Inferior Vena Cava in Patients with Iliac Venous Thrombosis , 2002, Annals of Internal Medicine.

[32]  H. Watson,et al.  Inferior vena cava malformation as a risk factor for deep venous thrombosis in the young , 2001, British journal of haematology.

[33]  J. Emmerich,et al.  Occult cancer in patients with bilateral deep-vein thrombosis , 1997, The Lancet.